



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

comorbidities (which were noted in 31 of the reported patients). Comparing with matched controls rather than predicted values would have been preferable. Yet the patients showed erratic increases in respiratory rate, with early CPET tachypnea as typically seen in PTS. There also was a tendency to decreased peripheral  $EO_2$ . This was wrongly calculated as arteriovenous  $O_2$  content differences (DavO2) divided by hemoglobin rather than by arterial  $O_2$  content, but characteristic anyway of deconditioning. Preload failure diagnosed in a subgroup of 7 patients disclosed vagotonic deconditioning as occurs in sedentary overweight subjects. Only 1 patient had upper limit of normal (at 1.97 WU) of pulmonary vascular resistance at exercise, not convincingly diagnostic of exercise-induced pulmonary hypertension.

Long COVID-19 and ME/CFS are patient advocacy-derived entities. Generously funded research to uncover their physiologic or biologic determinants (since 1987 for ME/CFS) has failed until now. Admirable efforts such as those reported by Mancini et al<sup>1</sup> should not distract from adequate attention to their dominant psychological components.

**\*Robert Naeije, MD**  
**Sergio Caravita, MD, PhD**  
\*Department of Pathophysiology

Faculty of Medicine  
808 Lennik Road  
B-1070 Brussels, Belgium  
E-mail: [rnaeije@gmail.com](mailto:rnaeije@gmail.com)

<https://doi.org/10.1016/j.jchf.2022.01.008>

© 2022 by the American College of Cardiology Foundation. Published by Elsevier.

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

## REFERENCES

1. Mancini DM, Brunjes DL, Lala A, Trivieri MG, Contreras JP, Natelson BH. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-coronavirus disease. *J Am Coll Cardiol HF*. 2022;9:927-937.
2. Naeije R, Caravita S. Phenotyping long COVID. *Eur Respir J*. 2021;58:2101763.

## REPLY: CPET for Long COVID-19



We appreciate the comments from Drs Naeije and Caravita and the citation of their work which was not available at the time our report was written.<sup>1</sup> Drs Naeije and Caravita are correct that we performed a detailed analysis of cardiopulmonary stress tests in 41 patients with long coronavirus disease-2019 (COVID-19).<sup>2</sup> Careful review of individual tests should not detract from our overall findings which showed ventilatory abnormalities in 88% of this cohort including 41% with elevated  $VE/VCO_2$ , 61% with hypocapnia, and 63% with disordered breathing. Deconditioning is generally not characterized by ventilatory changes. The mechanism underlying these ventilatory abnormalities remain unclear. Anxiety or psychological stress is one potential explanation for the hyperventilation, but altered chemosensitivity, lung thrombotic, or fibrotic changes are also possible. I think we can agree that more research is needed to clarify the significance of our findings and to help find an answer for those patients afflicted with long COVID-19 syndrome.

**\*Donna M. Mancini, MD**  
**Benjamin H. Natelson, MD**

\*Division of Cardiology  
Department of Medicine  
Mount Sinai School of Medicine  
1 Gustav Levy Place, Room 272  
New York, New York 10029, USA  
E-mail: [donna.mancini@mountsinai.org](mailto:donna.mancini@mountsinai.org)

<https://doi.org/10.1016/j.jchf.2022.01.009>

© 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

## REFERENCES

1. Naeije R, Caravita S. Phenotyping long COVID. *Eur Respir J*. 2021;58:2101763.
2. Mancini DM, Brunjes DL, Lala A, Trivieri MG, Contreras JP, Natelson BH. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-coronavirus disease. *J Am Coll Cardiol HF*. 2021;9(12):927-937.